Published in final edited form as:

DNA Repair (Amst). 2015 May ; 29: 47–55. doi:10.1016/j.dnarep.2015.02.012.

Eukaryotic DNA polymerase ζ

Alena V. Makarova^{1,2} and Peter M. Burgers^{1,*}

¹Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA

²Institute of Molecular Genetics, Russian Academy of Sciences (IMG RAS), Moscow, Kurchatov sq. 2, 123182, Russia

Abstract

This review focuses on eukaryotic DNA polymerase ζ (Pol ζ), the enzyme responsible for the bulk of mutagenesis in eukaryotic cells in response to DNA damage. Pol ζ is also responsible for a large portion of mutagenesis during normal cell growth, in response to spontaneous damage or to certain DNA structures and other blocks that stall DNA replication forks. Novel insights in mutagenesis have been derived from recent advances in the elucidation of the subunit structure of Pol ζ . The lagging strand DNA polymerase δ shares the small Pol31 and Pol32 subunits with the Rev3-Rev7 core assembly giving a four subunit Pol ζ complex that is the active form in mutagenesis. Furthermore, Pol ζ forms essential interactions with the mutasome assembly factor Rev1 and with proliferating cell nuclear antigen (PCNA). These interactions are modulated by posttranslational modifications such as ubiquitination and phosphorylation that enhance translesion synthesis (TLS) and mutagenesis.

Introduction

In the 1960s it was discovered that DNA damage induced mutagenesis is not a passive process in cells, but it arises as a result of enzymatic processes required the participation of several proteins [1–4]. These early bacterial studies were quickly followed up with studies in budding yeast, identifying several genes that were associated with a deficiency in mutagenesis after UV irradiation and treatment by chemical DNA damage agents [5–9]. Mutations in these genes demonstrated a reduced ability to undergo UV-induced reversion of the ochre-suppressible *arg1-17* allele, and are therefore called *REV* genes (*reversionless*). The *REV* genes include *REV1*, *REV3* and *REV7*. The *REV3* gene was shown to be required for the generation of as much as 96% of UV-induced mutations in yeast [6], as well as about half of spontaneous mutations [10]. The *REV3* gene encodes the catalytic subunit of DNA polymerase ζ (Pol ζ), the enzyme involved in mutagenic replication of damaged DNA [11,12]. The *REV3*-dependent damage-induced mutagenesis pathway is evolutionarily

© 2015 Published by Elsevier B.V.

*corresponding author: TEL: (314) 362-3872 FAX: (314) 362-71831, burgers@biochem.wustl.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

conserved in all eukaryotes [13]. However, while *REV3* is dispensable in yeast, deletion of the mouse *REV3L* gene causes embryonic lethality, revealing the essential role of Pol ζ in mammalian development [14,15]. In this review, we will discuss novel insights in the subunit structure and architecture of Pol ζ , its DNA polymerase activity on undamaged and damaged DNA templates, its role in mutagenesis provoked by specific DNA damaging agents, and the regulation of its activity.

Structure of Pol ζ

The *S. cerevisiae REV3* gene was isolated in 1989 and predicted to encode protein of Mr ~173 kDa with a sequence characteristic of DNA polymerase [11]. The human *REV3* gene encodes a protein of Mr ~353 kDa, about twice the mass of yeast protein [16]. The strong similarity in phenotypes of mutations in the yeast *REV3* and *REV7* genes indicated a possible functional collaboration of the Rev3 and Rev7 proteins. Indeed, in 1996 a heterodimeric complex of Rev3 and Rev7 was purified from yeast and characterized as the sixth eukaryotic DNA polymerase, Pol ζ [12]. Rev3 is a B-family DNA polymerase, like the catalytic subunits of the replicative polymerases, Pol α , Pol δ , and Pol ϵ [17]. However, Pol ζ lacks 3'-5'-exonucleolytic proofreading activity [12].

The small Rev7 subunit (Mr ~ 28 kDa) was shown to stimulate the catalytic activity of Rev3 by 20–30 fold, suggesting that this two-subunit complex was the minimal assembly required for Pol ζ activity *in vitro* [12]. Rev7 is a member of the HORMA (Hop1, Rev7, and Mad2) family of proteins [18]. The interaction between Rev3 and Rev7 had been mapped to a region N-terminal of the polymerase domain in Rev3 [12,19,20] (Figure 1). The Rev7 subunit also plays an important role in mediating interactions of Pol ζ with other proteins. In particular, Rev7 interacts with the Rev1 DNA polymerase, which is also an essential component of the damage-induced mutagenesis machinery [5,19,21–23]. Rev7 also interacts with the Cdc7-Dbf4 protein kinase (DDK) [24]. DDK is both essential for the initiation of DNA replication and for UV-mutagenesis [25]. Human Rev7 also interacts with transcription factor TFII-I [26]. Finally, Rev7 interacts with the spindle assembly checkpoint protein MAD2, suggesting a potential link between TLS and chromosome segregation [27].

In 2012, several groups demonstrated that, like the other three B-family polymerases, Pol ζ is a multisubunit complex [28–30]. These four eukaryotic DNA polymerase complexes (Pol α , δ , ϵ , and ζ) are characterized by the presence of a cysteine-rich C-terminal domain (CTD) in each of their catalytic subunits [31]. The N-terminal cysteine-cluster (CysA) has been proposed to bind zinc, whereas the C-terminal cluster (CysB) has been proposed to contain an iron-sulfur cluster [31,32]. The CysB motif of Pol3 is required for the interaction of Pol3 with its second subunit Pol31 [32,33], which in turn binds Pol32 [34–36]. The CTDs of Pol3 and Rev3 show very high sequence homology, suggesting that the interaction between Rev3 and Pol31 could be analogous to that between Pol3 and Pol31. Indeed, the four-subunit Pol ζ_4 complex was shown to be organized by interactions between Rev3 and Pol31, and between Pol31 and Pol32 [28–30,37]. Mutations in the CysB motif of Rev3 CTD disrupted Rev3-Pol31 interaction and resulted in a complete defect in damage induced mutagenesis in yeast [28,30].

The Pol31 and Pol32 accessory subunits play important roles in Pol ζ function *in vitro* and *in vivo*. The purified human and yeast Pol ζ_4 complex demonstrated ~5–10-fold and 30-fold increase in biochemical activity, respectively, and showed enhanced processivity in comparison to the Pol ζ_2 enzyme [30,37]. Moreover, the Pol31 and Pol32 subunits were shown to be required for PCNA-dependent TLS by Pol ζ [30]. However, Pol δ and Pol ζ show important differences in complex stabilities with regard to their Pol32 subunit. Deletion of the yeast *POL32* gene does not result in lethality, however, *pol32* strains show defects in DNA replication, are sensitive to replication inhibitors and DNA damaging agents, and are completely defective for UV- and MMS-mutagenesis [38,39]. In *pol32* mutants, a functional Pol3-Pol31 complex is still formed, but it shows reduced functionality in DNA replication [34,40,41]. In contrast, the Rev3-Pol31 interactions are dependent on the presence of Pol32, and therefore *pol32* mutants, like *rev3-cysB* mutants, only produce the two-subunit Rev3-Rev7 form of Pol ζ [30]. Because both *rev3-cysB* and *pol32* mutants are defective for mutagenesis, a plausible explanation for the mutagenesis defect of *pol32* is that the 2-subunit complex is inactive in this process. However, additional contributions by Pol δ to some forms of TLS that are abrogated in the *pol32* mutant may also exist.

A 3D structural model of yeast Pol ζ_4 based on electron microscopy reconstruction has been proposed [20]. With regard to its structural architecture, Pol ζ shows some similarities with high-fidelity replicative DNA polymerases [31,42,43]. The Pol ζ_4 model suggests an elongated bilobal architecture with separate catalytic and regulatory modules. The Rev3 catalytic core forms a large lobe which is connected to a small regulatory lobe of accessory subunits Rev7, Pol31 and Pol32 via a long linker. However, even though Pol ζ and Pol δ share the Pol31-Pol32 accessory subunits, a detailed comparison between their architectures reveals differences that may underlie their different functions in the cell. As mentioned above, Pol3 forms a stable complex with Pol31 alone [40], but Rev3 does not [30]. One possible explanation for the Pol32 requirement in forming a stable Pol ζ complex is that the Rev7 subunit interacts with the C-terminal region of Pol32 [20]. Therefore, Pol32 may contribute to complex stability through dual interactions with Rev7 and Pol31. Surprisingly, in a departure from the consensus view of the essentiality of the Pol ζ_4 complex for mutagenesis that followed from genetic and biochemical studies, a recent study by Siebler *et al.* showed that a *REV3* mutant lacking its entire CTD shows low but significant mutagenesis [44]. This mutagenesis is dependent on the catalytic activity of Rev3 and on the presence of both Pol32 and Rev1, as well as PCNA ubiquitination. Interestingly, this mutant shows maximal mutagenesis at low doses of UV light, and is defective at higher doses that show maximal mutagenesis in wild-type strains. That phenotype resembles the mutagenesis phenotype of a *pol32-PIP* in which the PCNA-interaction motif has been deleted [45]. One possible explanation for these paradoxical results is that the Rev7-Rev3 CTD complex retains residual interactions with Pol32 through binding to Rev7 [20].

Human *REV3L* and Pol ζ

The damage-induced mutagenesis pathway is evolutionarily conserved from yeast to mammals [46]. The human *REV3L* gene encodes a protein about twice the mass of yeast Rev3 [16]. As expected, the proteins show high homology in both the polymerase and the cysteine-rich carboxy-terminal domains, as well as limited homology in the N-terminal

domain (NTD) (Figure 1). However, a ~280 aa spacer region between the NTD and the exonuclease domain (Exo) in yeast Rev3 has been expanded to ~2000 aa in Rev3L. This part consists of mostly unstructured and low complexity regions, but it also contains the Rev7 binding domain and a positively charged domain (PCD), which is unique to vertebrate species (Figure 1). Deletion of ~800 aa of this internal region while retaining the PCD and the Rev7-binding domains, allowed the expression and purification of the human Pol ζ_4 complex [37]. This form has a subunit composition and biochemical properties similar to the yeast enzyme. The roles of the intervening inserts and the PCD remain to be determined.

Multiple experiments indicate that human Pol ζ has a similar cellular function to that of the yeast enzyme [16,47,48]. However, unlike yeast *REV3*, which is not essential for viability [11], disruption of *REV3L* in mice causes embryonic lethality revealing an important role of Pol ζ in cell proliferation and genomic stability even in the absence of environmentally induced damage [14,15,49]. Rev3-deficient embryos have retarded growth and die around mid-gestation. They demonstrate impaired mesoderm maintenance and a lack of hematopoietic cells [15]. They also accumulate double-stranded DNA breaks, chromosome translocations and show generalized p53-independent apoptosis [50,51].

The key function of Pol ζ in maintaining genome stability was further demonstrated in mice models with conditional and tissue-specific *REV3L* gene knockouts and downregulation of Rev3L mRNA. Conditional knockouts in adult mice enhanced spontaneous tumorigenesis [52]. Mice with epidermal disruption of *REV3L* developed skin tumors and failed to mount skin-regenerative responses [53]. Keratinocytes isolated from these mice demonstrated an increased UV sensitivity, accumulated DNA breaks and showed striking proliferation defects. Furthermore, mice expressing anti-sense transcripts to Rev3L mRNA show a reduction in somatic hypermutations in the IgV_H genes, suggesting that mutagenesis by Pol ζ is also required for robust immune development [54].

A tumor suppressor role for Pol ζ has also been indicated from studies in humans. A reduction of *REV3L* gene expression is associated with colon carcinomas [55]. A polymorphism in the 3'UTR of *REV3L* potentially affecting miRNA-mediated gene regulation contributes to lung cancer susceptibility [56]. Furthermore, Pol ζ is an important determinant for tumor resistance to chemotherapeutic agents in several types of human cancers [48,57–60]. Pol ζ is considered as a potential biomarker of chemoradiation resistance [61]. Testing of Pol ζ expression and its activity in patients may provide important diagnostic information and guide to a personalized therapeutic approach in cancer therapy. In support of this, downregulation of *REV3L* expression significantly enhanced the sensitivity of human cancer cells to cisplatin therapy [58,62]. Therefore, Pol ζ represents a promising target for the treatment of chemotherapy-resistant tumors.

Activities and fidelity of Pol ζ during normal cell growth

Pol ζ plays a significant role in maintaining genome integrity by protecting cells from DNA damaging agents and reducing cytotoxicity, but it does so at the expense of increased mutations. Yeast cell death by UV-damage is primarily prevented by the nucleotide excision repair machinery and by the activity of Pol η , which carries out TLS of UV-dimers in a

relatively error-free manner [63,64]. However, while Pol ζ activity contributes much less to the viability of UV-irradiated cells than Pol η does [63], Pol ζ is responsible for as much as 96% of mutations that are induced by UV irradiation [6]. Importantly, Pol ζ also is responsible for about half of spontaneous mutations [6,10]. These latter studies suggest that Pol ζ is a low fidelity enzyme compared to the other B-family DNA polymerases. Indeed, while an exonuclease domain can be identified in Rev3, Pol ζ lacks 3'-5' exonuclease proofreading activity [12]. Steady state kinetic analyses of dNTP incorporation and misincorporation by yeast Pol ζ on oligonucleotide substrates showed a robust discrimination (10^3 – 10^4 fold) against incorporation of the incorrect nucleotide on base-paired template-primers. However, Pol ζ showed only a 10–100 fold discrimination against extension of mismatched over matched template-primer termini [65]. Furthermore, the enzyme readily extended from primer termini positioned opposite template 8-Oxoguanine or O6-methylguanine residues [66]. Based on these types of studies, Pol ζ has been designated as an extender polymerase during TLS, designed to elongate primer termini that are positioned opposite base damage and non-instructional lesions.

Fidelity measurements of replication by Pol ζ on gapped plasmid DNA substrates in which many different sequence contexts were sampled, demonstrated a low fidelity of Pol ζ with single base substitution error rates of $\sim 10^{-3}$ [67]. These error rates are lower than those by Y-family DNA polymerases but much higher than those of replicative B-family DNA polymerases. Pol ζ is prone to generating A-dCMP, C-dCMP and G-dGMP mismatches *in vitro*. Consistently with these data, C–G to G–C transversions were shown to be a characteristic of Pol ζ mutagenesis *in vivo* [68,69]. Pol ζ also generates multiple single base errors clustered in short patches within 6–10 nucleotides. These complex mutations occur both *in vitro* [67] and *in vivo* [70–74]. The frequency of such complex mutations far exceeds that would be predicted based on the mutation rates for single mutations alone indicating that the first error increases the probability of additional errors. This indicates that Pol ζ contributes to mutagenesis *in vivo* by directly generating its own mismatches and then extending them.

These conclusions were underscored by the study of the L979F mutator allele of *REV3* in yeast that increases the mutation rate *in vitro* 5-fold compared to wild-type [75]. In yeast, the *rev3-L979F* mutant caused a 2–3 fold increase in spontaneous mutation rates and a several fold increase in UV-induced mutation rates [69,76]. The spectrum of mutations, in particular tandem base-pair and complex clustered mutations that are produced in yeast, when compared to those produced *in vitro*, strongly suggest that Pol ζ can perform mutagenic bypass of lesions during which it synthesizes processively a short track of error-prone DNA.

The role of Pol ζ in spontaneous mutagenesis can be explained the involvement of Pol ζ in the bypass of spontaneous damage in the cell. The increase in spontaneous mutations in the *rev3-L979F* mutator mutant is consistent with this explanation [69]. In addition, however, Pol ζ is recruited to sites of replication fork stalling when replisomes themselves are compromised. Most of the mutagenesis that is associated with mutant forms of Pol δ or Pol ϵ that have decreased stability or functionality, is dependent on Pol ζ [73,77]. This mutagenesis has been called DRIM for defective replisome-induced mutagenesis [73].

Compromised replisomes are expected to stall more frequently at non-B DNA structures, and in particular at short inverted repeats forming hairpin structures. These sites were shown to activate Pol ζ during DRIM [74]. The sites of replicative polymerase stalling at non-B DNA structures are associated with the high proportion of GC-CG transversions and complex mutations. Error-prone bypass of non-canonical DNA structures by Pol ζ often occurs *via* template-switching DNA synthesis and subsequent DNA strand realignment, followed by extension of mismatched primer termini by Pol ζ [74]. Exposure of yeast cells to the replication inhibitor hydroxyurea that results in depletion of the dNTP pool also causes a Pol ζ -dependent increase in mutagenesis [73]. The involvement of Pol ζ in the replication of non-damaged DNA after replication fork stalling may prevent the formation of double-stranded breaks and associated chromosome instability, at the cost of increased mutations.

The role of Pol ζ in TLS and damage induced mutagenesis

Genetic and biochemical studies have demonstrated that Pol ζ is involved in TLS and mutagenesis in response to a large variety of DNA damages. These studies are summarized in Table 1. Biochemical studies have shown that the TLS activity of the 4-subunit Pol ζ_4 is much more efficient than that of Pol ζ_2 [30,37], and additionally, that PCNA further enhances the bypass activity of Pol ζ_4 [30,78]. These considerable differences in biochemical properties of the different assemblies may explain why some investigators observed no or inefficient bypass of certain damages, such as abasic sites or pyrimidine dimers [79–81], whereas other investigators detected efficient bypass of the same types of DNA damage [12,30,37,78]. In addition, the efficiency of TLS by Pol ζ depends on the sequence context in which the lesion resides [82].

Pol ζ shows a high fidelity for the bypass of some lesions such as thymine glycol [83] and aflatoxin-derived N7-dG adducts [84], but low fidelity opposite other lesions, such as aflatoxin-derived FAPY-dG adducts [85]. For some damages such as T-T (6–4) photoproducts, other DNA polymerases such as Pol ι are more proficient at the insertion step across damage *in vitro*, while Pol ζ is more proficient in the extension step [83]. Which DNA polymerase actually carries out bypass synthesis of a specific form of UV damage has been studied in yeast by determining the exact sequence contexts of TLS in informative polymerase mutants [86]. In addition, complementary studies have been carried out by transforming yeast, or transfecting human cells with DNA plasmids containing that specific damage. In yeast, these experiments show a strong dependence on Pol ζ , particularly for pyrimidine dimers transformed into a mutant Pol η background [87,88]. However, in human cells they also indicate the involvement of other TLS polymerases such as Pol κ and Pol ι [89–91]. Therefore, whether a two-polymerase bypass mechanism operates during TLS may not only depend on the type of damage but also on the organism. Mammals, with their wealth of specialized bypass DNA polymerases may be more likely to use two-polymerase mechanisms than yeast, which only has the Pol η , Pol ζ and Rev1 TLS enzymes.

Mammalian Rev1, which is considered the scaffold on which the mutasome is built, has been shown to simultaneously interact with Pol ζ and with one of several Y-family DNA polymerases (Pol η , κ , or ι), which may facilitate multi-polymerase TLS [21,92–94].

However it is not clear whether yeast Rev1-Pol ζ and Pol η (yeast has no Pol κ or Pol ι) are present in one complex. One group reported an interaction between the little finger domain of Rev1 and Pol η [95]. However, another group failed to detect an interaction between these two yeast proteins while the interaction between the mammalian orthologs was readily observable [93].

Regulation of mutagenesis

Mutagenesis is regulated at several levels, including by post-translational modifications. The observation that Pol3 and Rev3 share the Pol31-Pol32 subunits has led to the proposal of a model in which Pol3 and Rev3 switch binding to damaged DNA-associated Pol31-Pol32 during TLS [28] (Figure 2). In this model, stalling of Pol δ at sites of damage induces dissociation of Pol3 from Pol31-Pol32 leaving the latter associated with the sites of damage, and thereby marking it for subsequent association of Rev3-Rev7, in order to facilitate TLS. In support of this model, studies of the stability of Pol δ after DNA damage have shown that the Pol3 subunit, but not Pol31-Pol32, is partially degraded in response to DNA damage [96]. It remains to be determined whether the Pol3 that is degraded is part of the soluble pool or chromatin-bound Pol3. The latter would be consistent with the model. Degradation is dependent on Def1, a ubiquitin-binding protein that previously had been identified as important for stimulating the proteasome-mediated degradation of RNA polymerase II after DNA damage, thereby promoting the efficiency of transcription coupled nucleotide excision repair [97]. A *def1* strain is defective for damage-induced mutagenesis, suggesting that Pol3 proteolysis may be involved in a polymerase switch mechanism [96] (Figure 2).

However the switching hypothesis does not explain how Pol ζ operates during TLS on the leading strand which is replicated by Pol ϵ [98,99]. In fact, if the switching hypothesis is correct, the implication would be that it is relegated to post-replicative gap filling synthesis, at least on the leading strand. Furthermore, the switching hypothesis also suggest the existence of the two-subunit form of Pol ζ , which only assembles into a four-subunit enzyme with Pol31-Pol32 at sites of DNA damage, from which Pol3 has previously been displaced. Instead, experiments in yeast indicate that a stable Pol ζ_4 complex exists in all phases of cell cycle, and imposing DNA damage does not alter the stability of a complex [30].

The DNA sliding clamp and processivity factor PCNA is a key regulator of Pol ζ activity. PCNA can contact Pol ζ through its Pol31/Pol32 accessory subunits. The functional interaction of Pol ζ with PCNA stimulates its DNA polymerase activity and DNA translesion synthesis [30,78]. *S. cerevisiae* Pol ζ interacts with PCNA through PCNA-interaction motif at the C-terminus of Pol32 and deletion of this motif attenuates PCNA-dependent TLS by Pol ζ *in vitro* [30], and damage-induced mutagenesis *in vivo* [45]. However, this Pol32 truncation only marginally affects PCNA-dependent replication by Pol δ [45]. Moreover, unlike other polymerases, Pol ζ binds a region of PCNA that is located near the monomer-monomer interface, and this interaction is disrupted in mutagenesis-defective PCNA mutants [30,77]. The utilization of different PCNA-binding modes by Pol ζ and Pol δ may underlie differences in the regulation of their activities *in vivo*.

Mutagenesis is regulated by ubiquitination of PCNA [100,101]. The damage-response ubiquitin conjugating-ligase heterodimer Rad6-Rad18 mono-ubiquitinates PCNA when excessive RPA-coated ssDNA is formed in response to DNA damage and replication fork stalling [102]. Mono-ubiquitinated PCNA shows an increased interaction with Rev1 [103,104]. Rev1 has both a PCNA and ubiquitin-binding domain, and mutations in either domain abrogate mutagenesis [105–107]. In contrast, Pol ζ does not show increased interactions with ubiquitinated PCNA [104], further emphasizing the essential role of Rev1 in mutagenesis.

Ubiquitin-binding motifs (UBMs) have not been found in any of the four Pol ζ subunits. Instead, mono-ubiquitination of PCNA likely exerts its TLS-promoting activity through Rev1. Rev1 interacts with PCNA through its BRCT-domain and through the polymerase-associated domain [106,108,109], and shows additional interactions with ubiquitinated PCNA through its UMB motif [107,110]. The affinity of Rev1 for mono-ubiquitinated PCNA is higher than that for unmodified PCNA, further emphasizing the essential role of Rev1 in mutagenesis [107,110,111].

In addition to Rad6-Rad18, other factors in the ubiquitin pathway are also required for mutagenesis, but their function is less well understood. Rad5 is important for mediating K63-linked poly-ubiquitination of PCNA by Mms2-Ubc13 in a damage tolerance pathway that controls error-free repair in a recombination-dependent manner [100,112,113]. Rad5 was shown to be important for UV-mutagenesis in a specific *arg4-17* reversion assay, but this activity was independent of the ubiquitin-ligase and helicase activities of Rad5 [114]. Rad5 is also important for the generation of mutations associated with the transformation of damage-containing plasmids in yeast [88,115]. In contrast, in a forwards mutation assay, *rad5* mutants were proficient for UV-mutagenesis [116]. Furthermore, in mammalian cells, the two orthologs of Rad5, HTLF and SHPRH suppress UV- and alkylation-mutagenesis, respectively [117]. Damage-induced mutagenesis is actually enhanced in cells depleted for these orthologs. Likewise, mouse knock-out strains of HTLF and SHPRH are proficient for somatic hypermutation, a hallmark of damage-induced mutagenesis [118].

Phosphorylation also plays a major role in the regulation of mutagenesis. Mutations in the Cdc7 or Dbf4 genes, which constitute the DDK kinase that is essential for initiation of DNA replication, show a strong defect in damage-induced mutagenesis [24,25,119,120]. One phosphorylation target of DDK is the Rev7 subunit, but it remains to be established whether phosphorylation of Rev7 is the critical switch for mutagenesis, or whether there are other significant Cdc7-mediated modifications [24]. In addition, the DNA damage checkpoint is involved in efficient mutagenesis under certain conditions. First, the 9-1-1 checkpoint clamp is required for UV-mutagenesis in non-dividing cells [121]. Second, while the 9-1-1 clamp is dispensable for UV-mutagenesis in dividing cells, in nucleotide excision repair-defective mutants 9-1-1 becomes required for UV-mutagenesis [122]. The 9-1-1 clamp loads onto a primer/template DNA containing a 5'-junction, which is the opposite loading polarity of PCNA [123]. Therefore, it is unlikely that 9-1-1 acts by stimulating Pol ζ activity, but rather by activating Mec1 to phosphorylate an important target that stimulates TLS [124]. Rev1 is one proposed target for Mec1 phosphorylation, but the essential modifications have not yet been identified [125,126].

Spontaneous mutagenesis and DRIM (defective replisome induced mutagenesis) are largely subject to similar regulatory controls compared to damage-induced mutagenesis. Like UV-mutagenesis, DRIM is dependent on PCNA ubiquitination. However, sumoylation of PCNA also contributes to the efficiency of DRIM [77]. Spontaneous Pol ζ -dependent mutagenesis depends on the 9-1-1 checkpoint clamp [127].

The regulatory aspects of mutagenesis in this review have mostly focused on the yeast *S. cerevisiae*. The basic machinery that carries out TLS is conserved in mammals [37]. Furthermore, the regulatory controls are also conserved in mammals. These include PCNA ubiquitination, as well as phosphorylation by the checkpoint kinase ATR and by Cdc7 [128]. Additional steps also exist. Spartan is a conserved mammalian protein that appears to be absent from yeast. It interacts both with Pol δ and with ubiquitinated PCNA, and negatively regulates mutagenesis [129–131]. In human cells Spartan depletion facilitates the formation of a complex between Rev1 and Pol ζ and enhances damage-induced mutagenesis [130]. The human transcription factor TFII-I binds the Rev7 subunit of Pol ζ as well as PCNA, and is required for TLS and DNA damage tolerance [26]. However, the TLS function of TFII-I appears to be independent of its role in transcription.

Conclusion

In this review, we have discussed the role of the DNA polymerase activity of Pol ζ on undamaged and on damaged DNA, and the biological significance of low fidelity and TLS activity of Pol ζ . We have focused on the structural organization of the Pol ζ complex and the regulation of its activity in yeast and in human cells. Novel insights in mutagenesis have been derived from recent advances in the definition of the subunit structure of Pol ζ . Latest studies reveal that with regard to its structural architecture, Pol ζ demonstrates a high similarity with the multisubunit high-fidelity replicative DNA polymerases, however preserves unique structural features that distinguish this enzyme from those other B-family polymerases. There exists a wide spectrum of interactions between Pol ζ subunits and its various binding partners. In addition, there are essential roles for posttranslational modifications in the regulation of Pol ζ function. The complexity in forming a functional Pol ζ mutasome in cells shows that the cell maintains a strict control of its mutagenic activity. However, in addition it may reflect a flexibility of the TLS machinery in order to carry out successful DNA synthesis opposite different types of DNA lesions and replication fork-stalling structures *in vivo*. Many mechanistic aspects of these type of Pol ζ control, especially in human cells, remain largely unknown. Therefore, structural studies and analyses of the mechanisms of regulation of Pol ζ function are important areas for future research.

Acknowledgments

Our research on mutagenesis has been supported by Grant GM032431 from the National Institutes of Health (to P.M.B.)

References

1. Witkin EM. Mutation-proof and mutation-prone modes of survival in derivatives of *Escherichia coli* B differing in sensitivity to ultraviolet light. *Brookhaven Symp Biol.* 1967; 20:17–55.
2. Miura A, Tomizawa JI. Studies on radiation-sensitive mutants of *E. coli*. 3. Participation of the rec system in induction of mutation by ultraviolet irradiation. *Mol Gen Genet.* 1968; 103:1–10. [PubMed: 4890247]
3. Bridges BA, Mottershead R. RecA +-dependent mutagenesis occurring before DNA replication in UV- and -irradiated *Escherichia coli*. *Mutat Res.* 1971; 13:1–8. [PubMed: 4938962]
4. Radman M. SOS repair hypothesis: phenomenology of an inducible DNA repair which is accompanied by mutagenesis. *Basic Life Sci.* 1975; 5A:355–367. [PubMed: 1103845]
5. Lemontt JF. Mutants of Yeast Defective in Mutation Induced by Ultraviolet Light. *Genetics.* 1971; 68:21–33. [PubMed: 17248528]
6. Lemontt JF. Induction of forward mutations in mutationally defective yeast. *Mol Gen Genet.* 1972; 119:27–42. [PubMed: 4564715]
7. Prakash L. Effect of Genes Controlling Radiation Sensitivity on Chemically Induced Mutations in *SACCHAROMYCES CEREVISIAE*. *Genetics.* 1976; 83:285–301. [PubMed: 17248715]
8. McKee RH, Lawrence CW. Genetic analysis of gamma-ray mutagenesis in yeast. I. Reversion in radiation-sensitive strains. *Genetics.* 1979; 93:361–373. [PubMed: 395027]
9. Lawrence CW, Das G, Christensen RB. REV7, a new gene concerned with UV mutagenesis in yeast. *Mol Gen Genet.* 1985; 200:80–85. [PubMed: 3897794]
10. Quah SK, von Borstel RC, Hastings PJ. The origin of spontaneous mutation in *Saccharomyces cerevisiae*. *Genetics.* 1980; 96:819–839. [PubMed: 7021317]
11. Morrison A, Christensen RB, Alley J, Beck AK, Bernstine EG, Lemontt JF, Lawrence CW. REV3, a *Saccharomyces cerevisiae* gene whose function is required for induced mutagenesis, is predicted to encode a nonessential DNA polymerase. *J Bacteriol.* 1989; 171:5659–5667. [PubMed: 2676986]
12. Nelson JR, Lawrence CW, Hinkle DC. Thymine-thymine dimer bypass by yeast dna polymerase zeta. *Science.* 1996; 272:1646–1649. [PubMed: 8658138]
13. Lawrence CW, Maher VM. Eukaryotic mutagenesis and translesion replication dependent on DNA polymerase zeta and Rev1 protein. *Biochem Soc Trans.* 2001; 29:187–191. [PubMed: 11356151]
14. Wittschleben J, Shivji MK, Lalani E, Jacobs MA, Marini F, Gearhart PJ, Rosewell I, Stamp G, Wood RD. Disruption of the developmentally regulated Rev3l gene causes embryonic lethality. *Curr Biol.* 2000; 10:1217–1220. [PubMed: 11050392]
15. Esposito G, Godindagger I, Klein U, Yaspo ML, Cumano A, Rajewsky K. Disruption of the Rev3l-encoded catalytic subunit of polymerase zeta in mice results in early embryonic lethality. *Curr Biol.* 2000; 10:1221–1224. [PubMed: 11050393]
16. Gibbs PE, McGregor WG, Maher VM, Nisson P, Lawrence CW. A human homolog of the *Saccharomyces cerevisiae* REV3 gene, which encodes the catalytic subunit of DNA polymerase zeta. *Proc Natl Acad Sci U S A.* 1998; 95:6876–6880. [PubMed: 9618506]
17. Burgers PM, Koonin EV, Bruford E, Blanco L, Burtis KC, Christman MF, Copeland WC, Friedberg EC, Hanaoka F, Hinkle DC, Lawrence CW, Nakanishi M, Ohmori H, Prakash L, Prakash S, Reynaud CA, Sugino A, Todo T, Wang Z, Weill JC, Woodgate R. Eukaryotic DNA polymerases: proposal for a revised nomenclature. *J Biol Chem.* 2001; 276:43487–43490. [PubMed: 11579108]
18. Aravind L, Koonin EV. The HORMA domain: a common structural denominator in mitotic checkpoints, chromosome synapsis and DNA repair. *Trends Biochem Sci.* 1998; 23:284–286. [PubMed: 9757827]
19. Hara K, Hashimoto H, Murakumo Y, Kobayashi S, Kogame T, Unzai S, Akashi S, Takeda S, Shimizu T, Sato M. Crystal structure of human REV7 in complex with a human REV3 fragment and structural implication of the interaction between DNA polymerase zeta and REV1. *J Biol Chem.* 2010; 285:12299–12307. [PubMed: 20164194]

20. Gomez-Llorente Y, Malik R, Jain R, Choudhury JR, Johnson RE, Prakash L, Prakash S, Ubarretxena-Belandia I, Aggarwal AK. The architecture of yeast DNA polymerase zeta. *Cell Rep.* 2013; 5:79–86. [PubMed: 24120860]
21. Murakumo Y, Ogura Y, Ishii H, Numata S, Ichihara M, Croce CM, Fishel R, Takahashi M. Interactions in the error-prone postreplication repair proteins hREV1, hREV3, and hREV7. *J Biol Chem.* 2001; 276:35644–35651. [PubMed: 11485998]
22. Acharya N, Haracska L, Johnson RE, Unk I, Prakash S, Prakash L. Complex formation of yeast Rev1 and Rev7 proteins: a novel role for the polymerase-associated domain. *Mol Cell Biol.* 2005; 25:9734–9740. [PubMed: 16227619]
23. Kikuchi S, Hara K, Shimizu T, Sato M, Hashimoto H. Structural basis of recruitment of DNA polymerase zeta by interaction between REV1 and REV7 proteins. *J Biol Chem.* 2012; 287:33847–33852. [PubMed: 22859296]
24. Brandao LN, Ferguson R, Santoro I, Jinks-Robertson S, Sclafani RA. The Role of Dbf4-Dependent Protein Kinase in DNA Polymerase zeta-Dependent Mutagenesis in *Saccharomyces cerevisiae*. *Genetics.* 2014; 197:1111–1122. [PubMed: 24875188]
25. Njagi GD, Kilbey BJ. cdc7-1 a temperature sensitive cell-cycle mutant which interferes with induced mutagenesis in *Saccharomyces cerevisiae*. *Mol Gen Genet.* 1982; 186:478–481. [PubMed: 6752657]
26. Fattah FJ, Hara K, Fattah KR, Yang C, Wu N, Warrington R, Chen DJ, Zhou P, Boothman DA, Yu H. The transcription factor TFII-I promotes DNA translesion synthesis and genomic stability. *PLoS Genet.* 2014; 10:e1004419. [PubMed: 24922507]
27. Murakumo Y, Roth T, Ishii H, Rasio D, Numata S, Croce CM, Fishel R. A human REV7 homolog that interacts with the polymerase zeta catalytic subunit hREV3 and the spindle assembly checkpoint protein hMAD2. *J Biol Chem.* 2000; 275:4391–4397. [PubMed: 10660610]
28. Baranovskiy AG, Lada AG, Siebler HM, Zhang Y, Pavlov YI, Tahirov TH. DNA polymerase delta and zeta switch by sharing accessory subunits of DNA polymerase delta. *J Biol Chem.* 2012; 287:17281–17287. [PubMed: 22465957]
29. Johnson RE, Prakash L, Prakash S. Pol31 and Pol32 subunits of yeast DNA polymerase delta are also essential subunits of DNA polymerase zeta. *Proc Natl Acad Sci U S A.* 2012; 109:12455–12460. [PubMed: 22711820]
30. Makarova AV, Stodola JL, Burgers PM. A four-subunit DNA polymerase zeta complex containing Pol delta accessory subunits is essential for PCNA-mediated mutagenesis. *Nucleic Acids Res.* 2012; 40:11618–11626. [PubMed: 23066099]
31. Klinge S, Nunez-Ramirez R, Llorca O, Pellegrini L. 3D architecture of DNA Pol alpha reveals the functional core of multi-subunit replicative polymerases. *EMBO J.* 2009; 28:1978–1987. [PubMed: 19494830]
32. Netz DJ, Stith CM, Stumpfig M, Kopf G, Vogel D, Genau HM, Stodola JL, Lill R, Burgers PM, Pierik AJ. Eukaryotic DNA polymerases require an iron-sulfur cluster for the formation of active complexes. *Nat Chem Biol.* 2011; 8:125–132. [PubMed: 22119860]
33. MacNeill SA, Moreno S, Reynolds N, Nurse P, Fantes PA. The fission yeast Cdc1 protein, a homologue of the small subunit of DNA polymerase delta, binds to Pol3 and Cdc27. *EMBO J.* 1996; 15:4613–4628. [PubMed: 8887553]
34. Gerik KJ, Li X, Pautz A, Burgers PM. Characterization of the two small subunits of *Saccharomyces cerevisiae* DNA polymerase delta. *J Biol Chem.* 1998; 273:19747–19755. [PubMed: 9677405]
35. Sanchez Garcia J, Ciufu LF, Yang X, Kearsey SE, MacNeill SA. The C-terminal zinc finger of the catalytic subunit of DNA polymerase delta is responsible for direct interaction with the B-subunit. *Nucleic Acids Res.* 2004; 32:3005–3016. [PubMed: 15173383]
36. Baranovskiy AG, Babayeva ND, Liston VG, Rogozin IB, Koonin EV, Pavlov YI, Vassilyev DG, Tahirov TH. X-ray structure of the complex of regulatory subunits of human DNA polymerase delta. *Cell Cycle.* 2008; 7:3026–3036. [PubMed: 18818516]
37. Lee YS, Gregory MT, Yang W. Human Pol zeta purified with accessory subunits is active in translesion DNA synthesis and complements Pol eta in cisplatin bypass. *Proc Natl Acad Sci U S A.* 2014; 111:2954–2959. [PubMed: 24449906]

38. Gerik KJ, Gary SL, Burgers PM. Overproduction and affinity purification of *Saccharomyces cerevisiae* replication factor C. *J Biol Chem.* 1997; 272:1256–1262. [PubMed: 8995429]
39. Huang ME, Rio AG, Galibert MD, Galibert F. Pol32, a subunit of *Saccharomyces cerevisiae* DNA polymerase delta, suppresses genomic deletions and is involved in the mutagenic bypass pathway. *Genetics.* 2002; 160:1409–1422. [PubMed: 11973297]
40. Burgers PM, Gerik KJ. Structure and processivity of two forms of *Saccharomyces cerevisiae* DNA polymerase delta. *J Biol Chem.* 1998; 273:19756–19762. [PubMed: 9677406]
41. Stith CM, Sterling J, Resnick MA, Gordenin DA, Burgers PM. Flexibility of eukaryotic Okazaki fragment maturation through regulated strand displacement synthesis. *J Biol Chem.* 2008; 283:34129–34140. [PubMed: 18927077]
42. Asturias FJ, Cheung IK, Sabouri N, Chilkova O, Wepplo D, Johansson E. Structure of *Saccharomyces cerevisiae* DNA polymerase epsilon by cryo-electron microscopy. *Nat Struct Mol Biol.* 2006; 13:35–43. [PubMed: 16369485]
43. Jain R, Hammel M, Johnson RE, Prakash L, Prakash S, Aggarwal AK. Structural insights into yeast DNA polymerase delta by small angle X-ray scattering. *J Mol Biol.* 2009; 394:377–382. [PubMed: 19818796]
44. Siebler HM, Lada AG, Baranovskiy AG, Tahirov TH, Pavlov YI. A novel variant of DNA polymerase zeta, Rev3DeltaC, highlights differential regulation of Pol32 as a subunit of polymerase delta versus zeta in *Saccharomyces cerevisiae*. *DNA Repair (Amst).* 2014
45. Johansson E, Garg P, Burgers PM. The Pol32 subunit of DNA polymerase delta contains separable domains for processive replication and proliferating cell nuclear antigen (PCNA) binding. *J Biol Chem.* 2004; 279:1907–1915. [PubMed: 14594808]
46. Lawrence CW, Maher VM. Mutagenesis in eukaryotes dependent on DNA polymerase zeta and Rev1p. *Philos Trans R Soc Lond B Biol Sci.* 2001; 356:41–46. [PubMed: 11205328]
47. Li Z, Zhang H, McManus TP, McCormick JJ, Lawrence CW, Maher VM. hREV3 is essential for error-prone translesion synthesis past UV or benzo[a]pyrene diol epoxide-induced DNA lesions in human fibroblasts. *Mutat Res.* 2002; 510:71–80. [PubMed: 12459444]
48. Wu F, Lin X, Okuda T, Howell SB. DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance. *Cancer Res.* 2004; 64:8029–8035. [PubMed: 15520212]
49. Bemark M, Khamlichi AA, Davies SL, Neuberger MS. Disruption of mouse polymerase zeta (Rev3) leads to embryonic lethality and impairs blastocyst development in vitro. *Curr Biol.* 2000; 10:1213–1216. [PubMed: 11050391]
50. Van Sloun PP, Varlet I, Sonneveld E, Boei JJ, Romeijn RJ, Eeken JC, De Wind N. Involvement of mouse Rev3 in tolerance of endogenous and exogenous DNA damage. *Mol Cell Biol.* 2002; 22:2159–2169. [PubMed: 11884603]
51. Wang J, Kajiura K, Kawamura K, Kimura M, Miyagishima H, Koseki H, Tagawa M. An essential role for REV3 in mammalian cell survival: absence of REV3 induces p53-independent embryonic death. *Biochem Biophys Res Commun.* 2002; 293:1132–1137. [PubMed: 12051777]
52. Wittschieben JP, Patil V, Glushets V, Robinson LJ, Kusewitt DF, Wood RD. Loss of DNA polymerase zeta enhances spontaneous tumorigenesis. *Cancer Res.* 2010; 70:2770–2778. [PubMed: 20215524]
53. Lange SS, Bedford E, Reh S, Wittschieben JP, Carbajal S, Kusewitt DF, DiGiovanni J, Wood RD. Dual role for mammalian DNA polymerase zeta in maintaining genome stability and proliferative responses. *Proc Natl Acad Sci U S A.* 2013; 110:E687–696. [PubMed: 23386725]
54. Diaz M, Verkoczy LK, Flajnik MF, Klinman NR. Decreased frequency of somatic hypermutation and impaired affinity maturation but intact germinal center formation in mice expressing antisense RNA to DNA polymerase zeta. *J Immunol.* 2001; 167:327–335. [PubMed: 11418667]
55. Brondello JM, Pillaire MJ, Rodriguez C, Gourraud PA, Selves J, Cazaux C, Piette J. Novel evidences for a tumor suppressor role of Rev3, the catalytic subunit of Pol zeta. *Oncogene.* 2008; 27:6093–6101. [PubMed: 18622427]
56. Zhang S, Chen H, Zhao X, Cao J, Tong J, Lu J, Wu W, Shen H, Wei Q, Lu D. REV3L 3'UTR 460 T>C polymorphism in microRNA target sites contributes to lung cancer susceptibility. *Oncogene.* 2012; 32:242–250. [PubMed: 22349819]

57. Lin X, Trang J, Okuda T, Howell SB. DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair. *Clin Cancer Res*. 2006; 12:563–568. [PubMed: 16428501]
58. Wang H, Zhang SY, Wang S, Lu J, Wu W, Weng L, Chen D, Zhang Y, Lu Z, Yang J, Chen Y, Zhang X, Chen X, Xi C, Lu D, Zhao S. REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy. *Neuro Oncol*. 2009; 11:790–802. [PubMed: 19289490]
59. Roos WP, Tsaalbi-Shtylik A, Tsaryk R, Guvercin F, de Wind N, Kaina B. The translesion polymerase Rev3L in the tolerance of alkylating anticancer drugs. *Mol Pharmacol*. 2009; 76:927–934. [PubMed: 19641035]
60. Sharma S, Shah NA, Joiner AM, Roberts KH, Canman CE. DNA polymerase zeta is a major determinant of resistance to platinum-based chemotherapeutic agents. *Mol Pharmacol*. 2012; 81:778–787. [PubMed: 22387291]
61. Shi TY, Yang L, Yang G, Tu XY, Wu X, Cheng X, Wei Q. DNA polymerase zeta as a potential biomarker of chemoradiation resistance and poor prognosis for cervical cancer. *Med Oncol*. 2013; 30:500. [PubMed: 23456618]
62. Adachi M, Ijichi K, Hasegawa Y, Ogawa T, Nakamura H, Yasui Y, Fukushima M, Ishizaki K. Hypersensitivity to cisplatin after hRev3 mRNA knockdown in head and neck squamous cell carcinoma cells. *Mol Med Rep*. 2008; 1:695–698. [PubMed: 21479472]
63. McDonald JP, Levine AS, Woodgate R. The *Saccharomyces cerevisiae* RAD30 gene, a homologue of *Escherichia coli* dinB and umuC, is DNA damage inducible and functions in a novel error-free postreplication repair mechanism. *Genetics*. 1997; 147:1557–1568. [PubMed: 9409821]
64. Johnson RE, Prakash S, Prakash L. Efficient bypass of a thymine-thymine dimer by yeast DNA polymerase, Poleta. *Science*. 1999; 283:1001–1004. [PubMed: 9974380]
65. Johnson RE, Washington MT, Haracska L, Prakash S, Prakash L. Eukaryotic polymerases iota and zeta act sequentially to bypass DNA lesions. *Nature*. 2000; 406:1015–1019. [PubMed: 10984059]
66. Haracska L, Prakash S, Prakash L. Yeast DNA polymerase zeta is an efficient extender of primer ends opposite from 7,8-dihydro-8-Oxoguanine and O6-methylguanine. *Molecular & Cellular Biology*. 2003; 23:1453–1459. [PubMed: 12556503]
67. Zhong X, Garg P, Stith CM, McElhinny SA, Kissling GE, Burgers PM, Kunkel TA. The fidelity of DNA synthesis by yeast DNA polymerase zeta alone and with accessory proteins. *Nucleic Acids Res*. 2006; 34:4731–4742. [PubMed: 16971464]
68. Pavlov YI, Shcherbakova PV, Kunkel TA. In vivo consequences of putative active site mutations in yeast DNA polymerases alpha, epsilon, delta, and zeta. *Genetics*. 2001; 159:47–64. [PubMed: 11560886]
69. Sakamoto AN, Stone JE, Kissling GE, McCulloch SD, Pavlov YI, Kunkel TA. Mutator alleles of yeast DNA polymerase zeta. *DNA Repair (Amst)*. 2007; 6:1829–1838. [PubMed: 17715002]
70. Harfe BD, Jinks-Robertson S. DNA polymerase zeta introduces multiple mutations when bypassing spontaneous DNA damage in *Saccharomyces cerevisiae*. *Mol Cell*. 2000; 6:1491–1499. [PubMed: 11163221]
71. Minesinger BK, Jinks-Robertson S. Roles of RAD6 epistasis group members in spontaneous polzeta-dependent translesion synthesis in *Saccharomyces cerevisiae*. *Genetics*. 2005; 169:1939–1955. [PubMed: 15687278]
72. Abdulovic AL, Minesinger BK, Jinks-Robertson S. The effect of sequence context on spontaneous Polzeta-dependent mutagenesis in *Saccharomyces cerevisiae*. *Nucleic Acids Res*. 2008; 36:2082–2093. [PubMed: 18276637]
73. Northam MR, Robinson HA, Kochenova OV, Shcherbakova PV. Participation of DNA polymerase zeta in replication of undamaged DNA in *Saccharomyces cerevisiae*. *Genetics*. 2010; 184:27–42. [PubMed: 19841096]
74. Northam MR, Moore EA, Mertz TM, Binz SK, Stith CM, Stepchenkova EI, Wendt KL, Burgers PM, Shcherbakova PV. DNA polymerases zeta and Rev1 mediate error-prone bypass of non-B DNA structures. *Nucleic Acids Res*. 2013; 42:290–306. [PubMed: 24049079]

75. Stone JE, Kissling GE, Lujan SA, Rogozin IB, Stith CM, Burgers PM, Kunkel TA. Low-fidelity DNA synthesis by the L979F mutator derivative of *Saccharomyces cerevisiae* DNA polymerase zeta. *Nucleic Acids Res.* 2009; 37:3774–3787. [PubMed: 19380376]
76. Stone JE, Lujan SA, Kunkel TA. DNA polymerase zeta generates clustered mutations during bypass of endogenous DNA lesions in *Saccharomyces cerevisiae*. *Environ Mol Mutagen.* 2012; 53:777–786. [PubMed: 22965922]
77. Northam MR, Garg P, Baitin DM, Burgers PM, Shcherbakova PV. A novel function of DNA polymerase zeta regulated by PCNA. *Embo J.* 2006; 25:4316–4325. [PubMed: 16957771]
78. Garg P, Stith CM, Majka J, Burgers PM. Proliferating Cell Nuclear Antigen Promotes Translesion Synthesis by DNA Polymerase {zeta}. *J Biol Chem.* 2005; 280:23446–23450. [PubMed: 15879599]
79. Haracska L, Unk I, Johnson RE, Johansson E, Burgers PM, Prakash S, Prakash L. Roles of yeast DNA polymerases delta and zeta and of Rev1 in the bypass of abasic sites. *Genes Dev.* 2001; 15:945–954. [PubMed: 11316789]
80. Guo D, Wu X, Rajpal DK, Taylor JS, Wang Z. Translesion synthesis by yeast DNA polymerase zeta from templates containing lesions of ultraviolet radiation and acetylaminofluorene. *Nucleic Acids Res.* 2001; 29:2875–2883. [PubMed: 11433034]
81. Acharya N, Johnson RE, Prakash S, Prakash L. Complex formation with Rev1 enhances the proficiency of *Saccharomyces cerevisiae* DNA polymerase zeta for mismatch extension and for extension opposite from DNA lesions. *Mol Cell Biol.* 2006; 26:9555–9563. [PubMed: 17030609]
82. Stone JE, Kumar D, Binz SK, Inase A, Iwai S, Chabes A, Burgers PM, Kunkel TA. Lesion bypass by *S. cerevisiae* Pol zeta alone. *DNA Repair (Amst).* 2011; 10:826–834. [PubMed: 21622032]
83. Johnson RE, Yu SL, Prakash S, Prakash L. Yeast DNA polymerase zeta (zeta) is essential for error-free replication past thymine glycol. *Genes Dev.* 2003; 17:77–87. [PubMed: 12514101]
84. Lin YC, Li L, Makarova AV, Burgers PM, Stone MP, Lloyd RS. Error-prone replication bypass of the primary aflatoxin B1 DNA adduct, AFB1-N7-Gua. *J Biol Chem.* 2014; 289:18497–18506. [PubMed: 24838242]
85. Lin YC, Li L, Makarova AV, Burgers PM, Stone MP, Lloyd RS. Molecular basis of aflatoxin-induced mutagenesis--role of the aflatoxin B1-formamidopyrimidine adduct. *Carcinogenesis.* 2014
86. Abdulovic AL, Jinks-Robertson S. The in vivo characterization of translesion synthesis across UV-induced lesions in *Saccharomyces cerevisiae*: insights into Pol zeta- and Pol eta-dependent frameshift mutagenesis. *Genetics.* 2006; 172:1487–1498. [PubMed: 16387871]
87. Gibbs PE, McDonald J, Woodgate R, Lawrence CW. The Relative Roles in Vivo of *Saccharomyces cerevisiae* Pol {eta}, Pol {zeta}, Rev1 Protein and Pol32 in the Bypass and Mutation Induction of an Abasic Site, T-T (6-4) Photoadduct and T-T cis-syn Cyclobutane Dimer. *Genetics.* 2005; 169:575–582. [PubMed: 15520252]
88. Pages V, Bresson A, Acharya N, Prakash S, Fuchs RP, Prakash L. Requirement of Rad5 for DNA polymerase zeta-dependent translesion synthesis in *Saccharomyces cerevisiae*. *Genetics.* 2008; 180:73–82. [PubMed: 18757916]
89. Ziv O, Geacintov N, Nakajima S, Yasui A, Livneh Z. DNA polymerase zeta cooperates with polymerases kappa and iota in translesion DNA synthesis across pyrimidine photodimers in cells from XPV patients. *Proc Natl Acad Sci U S A.* 2009; 106:11552–11557. [PubMed: 19564618]
90. Shachar S, Ziv O, Avkin S, Adar S, Wittschieben J, Reissner T, Chaney S, Friedberg EC, Wang Z, Carell T, Geacintov N, Livneh Z. Two-polymerase mechanisms dictate error-free and error-prone translesion DNA synthesis in mammals. *EMBO J.* 2009; 28:383–393. [PubMed: 19153606]
91. Livneh Z, Ziv O, Shachar S. Multiple two-polymerase mechanisms in mammalian translesion DNA synthesis. *Cell Cycle.* 2010; 9:729–735. [PubMed: 20139724]
92. Guo C, Fischhaber PL, Luk-Paszyc MJ, Masuda Y, Zhou J, Kamiya K, Kisker C, Friedberg EC. Mouse Rev1 protein interacts with multiple DNA polymerases involved in translesion DNA synthesis. *Embo J.* 2003; 22:6621–6630. [PubMed: 14657033]
93. Kosarek JN, Woodruff RV, Rivera-Begeman A, Guo C, D'Souza S, Koonin EV, Walker GC, Friedberg EC. Comparative analysis of in vivo interactions between Rev1 protein and other Y-family DNA polymerases in animals and yeasts. *DNA Repair (Amst).* 2008; 7:439–451. [PubMed: 18242152]

94. Wojtaszek J, Lee CJ, D'Souza S, Minesinger B, Kim H, D'Andrea AD, Walker GC, Zhou P. Structural basis of Rev1-mediated assembly of a quaternary vertebrate translesion polymerase complex consisting of Rev1, heterodimeric polymerase (Pol) zeta, and Pol kappa. *J Biol Chem.* 2012; 287:33836–33846. [PubMed: 22859295]
95. Acharya N, Haracska L, Prakash S, Prakash L. Complex formation of yeast Rev1 with DNA polymerase eta. *Mol Cell Biol.* 2007; 27:8401–8408. [PubMed: 17875922]
96. Daraba A, Gali VK, Halmi M, Haracska L, Unk I. Def1 promotes the degradation of Pol3 for polymerase exchange to occur during DNA-damage--induced mutagenesis in *Saccharomyces cerevisiae*. *PLoS Biol.* 2014; 12:e1001771. [PubMed: 24465179]
97. Woudstra EC, Gilbert C, Fellows J, Jansen L, Brouwer J, Erdjument-Bromage H, Tempst P, Svejstrup JQ. A Rad26-Def1 complex coordinates repair and RNA pol II proteolysis in response to DNA damage. *Nature.* 2002; 415:929–933. [PubMed: 11859374]
98. Kunkel TA, Burgers PM. Dividing the workload at a eukaryotic replication fork. *Trends Cell Biol.* 2008; 18:521–527. [PubMed: 18824354]
99. Pursell ZF, Isoz I, Lundstrom EB, Johansson E, Kunkel TA. Yeast DNA polymerase epsilon participates in leading-strand DNA replication. *Science.* 2007; 317:127–130. [PubMed: 17615360]
100. Hoege C, Pfander B, Moldovan GL, Pyrowolakis G, Jentsch S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. [comment]. *Nature.* 2002; 419:135–141. [PubMed: 12226657]
101. Stelter P, Ulrich HD. Control of spontaneous and damage-induced mutagenesis by SUMO and ubiquitin conjugation. *Nature.* 2003; 425:188–191. [PubMed: 12968183]
102. Davies AA, Huttner D, Daigaku Y, Chen S, Ulrich HD. Activation of ubiquitin-dependent DNA damage bypass is mediated by replication protein a. *Mol Cell.* 2008; 29:625–636. [PubMed: 18342608]
103. Bienko M, Green CM, Crosetto N, Rudolf F, Zapart G, Coull B, Kannouche P, Wider G, Peter M, Lehmann AR, Hofmann K, Dikic I. Ubiquitin-binding domains in Y-family polymerases regulate translesion synthesis. *Science.* 2005; 310:1821–1824. [PubMed: 16357261]
104. Garg P, Burgers PM. Ubiquitinated proliferating cell nuclear antigen activates translesion DNA polymerases eta and REV1. *Proc Natl Acad Sci U S A.* 2005; 102:18361–18366. [PubMed: 16344468]
105. Edmunds CE, Simpson LJ, Sale JE. PCNA ubiquitination and REV1 define temporally distinct mechanisms for controlling translesion synthesis in the avian cell line DT40. *Mol Cell.* 2008; 30:519–529. [PubMed: 18498753]
106. Ross AL, Simpson LJ, Sale JE. Vertebrate DNA damage tolerance requires the C-terminus but not BRCT or transferase domains of REV1. *Nucleic Acids Res.* 2005; 33:1280–1289. [PubMed: 15741181]
107. Wood A, Garg P, Burgers PM. A ubiquitin-binding motif in the translesion DNA polymerase Rev1 mediates its essential functional interaction with ubiquitinated proliferating cell nuclear antigen in response to DNA damage. *J Biol Chem.* 2007; 282:20256–20263. [PubMed: 17517887]
108. Pustovalova Y, Maciejewski MW, Korzhnev DM. NMR mapping of PCNA interaction with translesion synthesis DNA polymerase Rev1 mediated by Rev1-BRCT domain. *J Mol Biol.* 2013; 425:3091–3105. [PubMed: 23747975]
109. Sharma NM, Kochenova OV, Shcherbakova PV. The non-canonical protein binding site at the monomer-monomer interface of yeast proliferating cell nuclear antigen (PCNA) regulates the Rev1-PCNA interaction and Polzeta/Rev1-dependent translesion DNA synthesis. *J Biol Chem.* 2011; 286:33557–33566. [PubMed: 21799021]
110. Guo C, Tang TS, Bienko M, Parker JL, Bielen AB, Sonoda E, Takeda S, Ulrich HD, Dikic I, Friedberg EC. Ubiquitin-binding motifs in REV1 protein are required for its role in the tolerance of DNA damage. *Mol Cell Biol.* 2006; 26:8892–8900. [PubMed: 16982685]
111. Guo C, Sonoda E, Tang TS, Parker JL, Bielen AB, Takeda S, Ulrich HD, Friedberg EC. REV1 protein interacts with PCNA: significance of the REV1 BRCT domain in vitro and in vivo. *Mol Cell.* 2006; 23:265–271. [PubMed: 16857592]

112. Ulrich HD. The srs2 suppressor of UV sensitivity acts specifically on the RAD5- and MMS2-dependent branch of the RAD6 pathway. *Nucleic Acids Res.* 2001; 29:3487–3494. [PubMed: 11522817]
113. Broomfield S, Xiao W. Suppression of genetic defects within the RAD6 pathway by Srs2 is specific for error-free post-replication repair but not for damage-induced mutagenesis. *Nucleic Acids Res.* 2002; 30:732–739. [PubMed: 11809886]
114. Gangavarapu V, Haracska L, Unk I, Johnson RE, Prakash S, Prakash L. Mms2-Ubc13-dependent and -independent roles of Rad5 ubiquitin ligase in postreplication repair and translesion DNA synthesis in *Saccharomyces cerevisiae*. *Mol Cell Biol.* 2006; 26:7783–7790. [PubMed: 16908531]
115. Kuang L, Kou H, Xie Z, Zhou Y, Feng X, Wang L, Wang Z. A non-catalytic function of Rev1 in translesion DNA synthesis and mutagenesis is mediated by its stable interaction with Rad5. *DNA Repair (Amst).* 2013; 12:27–37. [PubMed: 23142547]
116. Halas A, Podlaska A, Derkacz J, McIntyre J, Skoneczna A, Sledziewska-Gojska E. The roles of PCNA SUMOylation, Mms2-Ubc13 and Rad5 in translesion DNA synthesis in *Saccharomyces cerevisiae*. *Mol Microbiol.* 2011; 80:786–797. [PubMed: 21362066]
117. Lin JR, Zeman MK, Chen JY, Yee MC, Cimprich KA. SHPRH and HLTF act in a damage-specific manner to coordinate different forms of postreplication repair and prevent mutagenesis. *Mol Cell.* 2011; 42:237–249. [PubMed: 21396873]
118. Krijger PH, Lee KY, Wit N, van den Berk PC, Wu X, Roest HP, Maas A, Ding H, Hoeijmakers JH, Myung K, Jacobs H. HLTF and SHPRH are not essential for PCNA polyubiquitination, survival and somatic hypermutation: existence of an alternative E3 ligase. *DNA Repair (Amst).* 2011; 10:438–444. [PubMed: 21269891]
119. Pessoa-Brandao L, Sclafani RA. CDC7/DBF4 functions in the translesion synthesis branch of the RAD6 epistasis group in *Saccharomyces cerevisiae*. *Genetics.* 2004; 167:1597–1610. [PubMed: 15342501]
120. Dolan WP, Le AH, Schmidt H, Yuan JP, Green M, Forsburg SL. Fission yeast Hsk1 (Cdc7) kinase is required after replication initiation for induced mutagenesis and proper response to DNA alkylation damage. *Genetics.* 2010; 185:39–53. [PubMed: 20176980]
121. Kozmin SG, Jinks-Robertson S. The mechanism of nucleotide excision repair-mediated UV-induced mutagenesis in nonproliferating cells. *Genetics.* 2013; 193:803–817. [PubMed: 23307894]
122. Paulovich AG, Armour CD, Hartwell LH. The *Saccharomyces cerevisiae* RAD9, RAD17, RAD24 and MEC3 genes are required for tolerating irreparable, ultraviolet-induced DNA damage. *Genetics.* 1998; 150:75–93. [PubMed: 9725831]
123. Majka J, Binz SK, Wold MS, Burgers PM. Replication protein A directs loading of the DNA damage checkpoint clamp to 5'-DNA junctions. *J Biol Chem.* 2006; 281:27855–27861. [PubMed: 16864589]
124. Majka J, Niedziela-Majka A, Burgers PM. The checkpoint clamp activates Mec1 kinase during initiation of the DNA damage checkpoint. *Mol Cell.* 2006; 24:891–901. [PubMed: 17189191]
125. Pages V, Santa Maria SR, Prakash L, Prakash S. Role of DNA damage-induced replication checkpoint in promoting lesion bypass by translesion synthesis in yeast. *Genes Dev.* 2009; 23:1438–1449. [PubMed: 19528320]
126. Sabbioneda S, Bortolomai I, Giannattasio M, Plevani P, Muzi-Falconi M. Yeast Rev1 is cell cycle regulated, phosphorylated in response to DNA damage and its binding to chromosomes is dependent upon MEC1. *DNA Repair (Amst).* 2007; 6:121–127. [PubMed: 17035102]
127. Sabbioneda S, Minesinger BK, Giannattasio M, Plevani P, Muzi-Falconi M, Jinks-Robertson S. The 9-1-1 checkpoint clamp physically interacts with polzeta and is partially required for spontaneous polzeta-dependent mutagenesis in *Saccharomyces cerevisiae*. *J Biol Chem.* 2005; 280:38657–38665. [PubMed: 16169844]
128. Yamada M, Watanabe K, Mistrik M, Vesela E, Protivankova I, Mailand N, Lee M, Masai H, Lukas J, Bartek J. ATR-Chk1-APC/CCdh1-dependent stabilization of Cdc7-ASK (Dbf4) kinase is required for DNA lesion bypass under replication stress. *Genes Dev.* 2013; 27:2459–2472. [PubMed: 24240236]

129. Juhasz S, Balogh D, Hajdu I, Burkovics P, Villamil MA, Zhuang Z, Haracska L. Characterization of human Spartan/C1orf124, an ubiquitin-PCNA interacting regulator of DNA damage tolerance. *Nucleic Acids Res.* 2012; 40:10795–10808. [PubMed: 22987070]
130. Kim MS, Machida Y, Vashisht AA, Wohlschlegel JA, Pang YP, Machida YJ. Regulation of error-prone translesion synthesis by Spartan/C1orf124. *Nucleic Acids Res.* 2012; 41:1661–1668. [PubMed: 23254330]
131. Machida Y, Kim MS, Machida YJ. Spartan/C1orf124 is important to prevent UV-induced mutagenesis. *Cell Cycle.* 2012; 11:3395–3402. [PubMed: 22894931]
132. Auerbach PA, Demple B. Roles of Rev1, Pol zeta, Pol32 and Pol eta in the bypass of chromosomal abasic sites in *Saccharomyces cerevisiae*. *Mutagenesis.* 2009; 25:63–69. [PubMed: 19901007]
133. Chan K, Resnick MA, Gordenin DA. The choice of nucleotide inserted opposite abasic sites formed within chromosomal DNA reveals the polymerase activities participating in translesion DNA synthesis. *DNA Repair (Amst).* 2013; 12:878–889. [PubMed: 23988736]
134. Yuan F, Zhang Y, Rajpal DK, Wu X, Guo D, Wang M, Taylor JS, Wang Z. Specificity of DNA lesion bypass by the yeast DNA polymerase eta. *J Biol Chem.* 2000; 275:8233–8239. [PubMed: 10713149]
135. McNally K, Neal JA, McManus TP, McCormick JJ, Maher VM. hRev7, putative subunit of hPolzeta, plays a critical role in survival, induction of mutations, and progression through S-phase, of UV((254nm))-irradiated human fibroblasts. *DNA Repair (Amst).* 2008; 7:597–604. [PubMed: 18295554]
136. Kamiya H. Mutagenicity of oxidized DNA precursors in living cells: Roles of nucleotide pool sanitization and DNA repair enzymes, and translesion synthesis DNA polymerases. *Mutat Res.* 2010; 703:32–36. [PubMed: 20542139]
137. You C, Swanson AL, Dai X, Yuan B, Wang J, Wang Y. Translesion synthesis of 8,5'-cyclopurine-2'-deoxynucleosides by DNA polymerases eta, iota, and zeta. *J Biol Chem.* 2013; 288:28548–28556. [PubMed: 23965998]
138. Monti P, Ciribilli Y, Russo D, Bisio A, Perfumo C, Andreotti V, Menichini P, Inga A, Huang X, Gold B, Fronza G. Rev1 and Polzeta influence toxicity and mutagenicity of Melex, a sequence selective N3-adenine methylating agent. *DNA Repair (Amst).* 2008; 7:431–438. [PubMed: 18182332]
139. Washington MT, Minko IG, Johnson RE, Haracska L, Harris TM, Lloyd RS, Prakash S, Prakash L. Efficient and error-free replication past a minor-groove N2-guanine adduct by the sequential action of yeast Rev1 and DNA polymerase zeta. *Mol Cell Biol.* 2004; 24:6900–6906. [PubMed: 15282292]
140. Fernandes PH, Lloyd RS. Mutagenic bypass of the butadiene-derived 2'-deoxyuridine adducts by polymerases eta and zeta. *Mutat Res.* 2007; 625:40–49. [PubMed: 17586533]
141. Grossmann KF, Ward AM, Matkovic ME, Folias AE, Moses RE. *S. cerevisiae* has three pathways for DNA interstrand crosslink repair. *Mutat Res.* 2001; 487:73–83. [PubMed: 11738934]
142. O'Brien TJ, Witcher P, Brooks B, Patierno SR. DNA polymerase zeta is essential for hexavalent chromium-induced mutagenesis. *Mutat Res.* 2009; 663:77–83. [PubMed: 19428373]
143. Raschle M, Knipscheer P, Enoiu M, Angelov T, Sun J, Griffith JD, Ellenberger TE, Scharer OD, Walter JC. Mechanism of replication-coupled DNA interstrand crosslink repair. *Cell.* 2008; 134:969–980. [PubMed: 18805090]
144. Nelson JR, Lawrence CW, Hinkle DC. Deoxycytidyl transferase activity of yeast rev1 protein. *Nature.* 1996; 382:729–731. [PubMed: 8751446]
145. Zhou Y, Wang J, Zhang Y, Wang Z. The catalytic function of the Rev1 dCMP transferase is required in a lesion-specific manner for translesion synthesis and base damage-induced mutagenesis. *Nucleic Acids Res.* 2010; 38:5036–5046. [PubMed: 20388628]
146. Bermudez VP, MacNeill SA, Tappin I, Hurwitz J. The influence of the Cdc27 subunit on the properties of the *Schizosaccharomyces pombe* DNA polymerase delta. *J Biol Chem.* 2002; 277:36853–36862. [PubMed: 12124382]

147. Hughes P, Tratner I, Ducoux M, Piard K, Baldacci G. Isolation and identification of the third subunit of mammalian DNA polymerase delta by PCNA-affinity chromatography of mouse FM3A cell extracts. *Nucleic Acids Res.* 1999; 27:2108–2114. [PubMed: 10219083]
148. Cejka P, Vondrejs V, Storchova Z. Dissection of the functions of the *Saccharomyces cerevisiae* RAD6 postreplicative repair group in mutagenesis and UV sensitivity. *Genetics.* 2001; 159:953–963. [PubMed: 11729144]
149. Nair DT, Johnson RE, Prakash L, Prakash S, Aggarwal AK. Rev1 employs a novel mechanism of DNA synthesis using a protein template. *Science.* 2005; 309:2219–2222. [PubMed: 16195463]
150. Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF, Koonin EV. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. *Faseb J.* 1997; 11:68–76. [PubMed: 9034168]
151. Warbrick E, Lane DP, Glover DM, Cox LS. A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. *Curr Biol.* 1995; 5:275–282. [PubMed: 7780738]

Figure 1. Structural organization of Pol ζ and Rev1

The domain structure of *S. cerevisiae* and human Pol ζ and Rev1 are shown. Subunit-subunit interaction motifs and interactions with (ubiquitinated) PCNA are indicated. NTD – N-terminal domain, CTD – C-terminal domain, exo – inactive 3'-5' exonuclease domain [11,12], pol – DNA polymerase domain, PCD – positively charged domain [16,37], HORMA – Hop1, Rev7, and Mad2 family domain [18], OB – oligonucleotide-oligosaccharide binding fold [36], PDE – phosphodiesterase domain [36], oligonucleotide-oligosaccharide binding fold PAD – polymerase associated domain [149], BRCT – BRCA1 C terminal domain [150], PIP – PCNA-interacting motif [151], UBM – ubiquitin binding motif [103,107]. Conservative Cys residues coordinating [Zn] and [4Fe-4S] clusters [32].

Figure 2. Two models for Pol ζ recruitment to DNA damage sites
See text for details.

Table 1TLS activities of Pol ζ *in vivo* and *in vitro*

DNA damage	organism	Pol ζ TLS <i>in vivo</i>	Pol ζ TLS <i>in vitro</i>
Abasic sites	yeast	participates in mutagenic TLS opposite AP-sites [87,132,133]	- bypasses AP-sites [82] bypass is stimulated by PCNA [30,78]
	human		yeast Pol ζ cooperates with hPol ι and hPol η to bypass AP-sites [83,134]
Photo-products	yeast	mediates survival and mutagenesis after UV irradiation [6], bypasses T-T (6-4) but not T-T cis-syn photoproducts [87]	bypasses cis-syn T-T dimers and T-T (6-4) photoproducts alone in [12,82], stimulated by PCNA [78]
	human	mediates survival and mutagenesis after UV irradiation [16,47,135]	yeast Pol ζ cooperates with hPol ι and hPol η to bypass T-T (6-4) photoproducts [83]
Ionizing radiation and oxidative stress	yeast	mediates mutagenesis induced by ionizing radiation [8], participates in TLS opposite thymine-glycols [83]	bypasses thymine-glycol with relatively high fidelity [83]; as primer termini extender yeast Pol ζ cooperates with Pol δ to bypass 8-oxo-G and O ⁶ -meG [66]
	human	mediates mutagenesis induced by 8-oxo-dGTP [136]	yeast Pol ζ cooperates with hPol ι to bypass 8,5'-cyclopurines [137]
chemical carcinogens	yeast	mediates mutagenesis induced by 4-NQO and MMS [7,9], mediates mutagenic TLS opposite 3-meA [138]	bypasses AFB1-N7-dG adducts with high fidelity and AFB1-FAPY-dG adducts with low fidelity [84,85], cooperates with Rev1 to accurately bypass N2 minor groove γ -HOP-dG adducts [139], bypasses AAF-dG adduct with low accuracy [80]
	human	mediates mutagenesis induced by BPDE [47]	yeast Pol ζ cooperates with hPol η to bypass butadiene-derived uridine adducts [140]
Interstrand crosslinks	yeast	mediates cis-platin and hexavalent chromium toxicity and mutagenesis [141,142]; required for ICL repair [141]	
	human, frog	mediates cisplatin cytotoxicity and mutagenesis [48]	Xenopus Pol ζ required for ICL bypass [143]

Table 2

Yeast genes required for mutagenesis.

Yeast gene	Function	References
<i>REV1</i>	deoxycytidyl transferase and mutasome organizer; binds Rev7 and ubiquitinated PCNA.	[21,23,94,107,110,111,144,145]
<i>REV3</i>	catalytic subunit of Pol ζ .	[11,12]
<i>REV7</i>	Accessory subunit of Pol ζ	[12]
<i>POL31/POL32</i>	Accessory subunits of Pol ζ and Pol δ ; Pol31 binds Rev3, Pol32 binds Rev7 and PCNA.	[20,28–30,34,45]
<i>POL30</i>	PCNA, the DNA sliding clamp and processivity factor, interacts with Pol32 and with Rev1	[45,106,107,110,111,146,147]
<i>RAD6/RAD18</i>	E2/E3 that mono-ubiquitinates PCNA	[100,101]
<i>RAD5</i>	Involved in poly-ubiquitination of PCNA. Required for mutagenesis in some studies, but not in others.	[71,88,114–118,121,148]
<i>DEF1</i>	Enhancer of ubiquitination for degradation; destabilizes Pol3 after damage.	[96,97]
<i>CDC7/DBF4</i>	Cell cycle protein kinase (DDK) in replication initiation; required for mutagenesis.	[24,25,119]
<i>MEC1/DDC2</i>	Checkpoint kinase, ortholog of ATR/ATM; required for mutagenesis in nucleotide-excision-repair defective mutants.	[125]
<i>RAD17/MEC3//DDC1-RAD24</i>	DNA damage 9-1-1 checkpoint clamp/clamp loader; required for mutagenesis in nucleotide-excision-repair defective mutants.	[122,127]